InnovationRx: Phil Knight’s $2 Billion Cancer Gifthttps://t.co/r5eeEHj1ep https://t.co/LLW9O7L9Q8 ...

RT Bloomberg New Economy (@BBGNewEconomy).@BBGNewEconomy launched the Pan-American Cancer Consortium with @AstraZeneca.The goal: scale cross-border tumor boards, expand trial access & build equitable cancer care across the Americas.Read more here. https://t.co/tZwiUjLyjg https://t.co/NmQCGW9wgM ...

Philanthropy - Phil Knight donates $2 billion to Oregon cancer center [1]

The California-based startup Tahoe Therapeutics, now valued at $120 million, has developed a scalable way to quickly generate crucial biological data needed for AI models–and use them to find new cures for cancer. (Photo: Tahoe Therapeutics)https://t.co/fnTK9S6xnA https://t.co/BkC8go1FDc ...

AI in Scientific Research - GPT5 predicts experiment outcomes, potentially saving weeks or months in research [1] - GPT5 is considered a collaborator and mentor, possessing knowledge exceeding that of experts in their fields [2] - GPT5 provides insights and suggests follow-up experiments, accelerating scientific progress [3][4] - GPT5 facilitates brainstorming and critiques ideas, enhancing the collaborative research process [4][5] Impact on Healthcare - GPT5 may empower patients by helping them advocate for themselves and feel more confident in discussions with doctors [5] - AI models like GPT5 evoke strong emotional responses, fostering confidence in achieving research goals [5]

Former Citigroup Chair Sandy Weill’s New $100 Million Gift To Harness AI For A West Coast Cancer Hub https://t.co/wIKFjU6EoD https://t.co/wIKFjU6EoD ...

Funding & Collaboration - The Weill Family Foundation donated $100 million to two Bay Area universities for cancer research [1] - The donation aims to advance cancer research and treatment through four specific projects [1]

Two Bay Area universities announced a $100 million gift from the Weill Family Foundation for a new cancer hub that is designed to advance cancer research and treatment via four specific projects. (Photo: Krista Kennell/Patrick McMullan via Getty Images)https://t.co/oI93tqBy4f https://t.co/NPx8eqUoYP ...

Company Overview - Caris Life Sciences, a cancer diagnostic firm, is set to list on the NASDAQ after pricing its IPO at $21 per share, above the expected range [1] - The company focuses on using AI and life sciences to identify tumors and find unique ways to deal with cancer tumors [2] - Caris Life Sciences positions itself as a world leader in molecular research and cancer, analyzing every gene on every cancer patient [3] Technology and Methodology - The company sequences genes from over 500,000 patients to correlate patient outcomes with genetic features, using AI to identify key features and develop diagnostic signatures [3][4] - Caris Life Sciences utilizes an AI with 218 different algorithms for feature selection, creating signatures for diagnosis and identifying drug targets [4] - The company is developing early diagnostic tests, such as for stage one and two breast cancer, using blood tests for earlier detection [5] - Caris Life Sciences differentiates itself by analyzing every gene (DNA and RNA) in blood and tissue, unlike competitors using smaller gene panels [6] Clinical Impact and Results - Caris Life Sciences claims its AI insights for triple-negative breast cancer can triple overall survival for 15% of the population, from one year to three years, using a 600-gene signature [7] - The company leverages a mature population dataset since 2019, incorporating AI since 2015 [8] - Therapeutic selection or recommendation to the oncologist based upon the molecular makeup of the tumor biopsy [13] - For a certain population, if they'll go with an IO and a chemo they'll live three years instead of one year [14] Business Model and Market - The company's revenue was up 35% to $400 million, primarily from profiling individual tumor biopsies to make therapeutic recommendations [13] - Caris Life Sciences collaborates with 97 members of its precision oncology alliance, including major cancer centers [15] - Future business lines include selling data and drug targets to pharmaceutical companies [16] - The company estimates its total addressable market is potentially $150 billion [17]

Cancer Research & Community Care - The speaker emphasizes the importance of community-based cancer care, noting that 80-85% of the nation's cancer care is delivered in community settings [4][5] - Cancer research is also significantly community-based, with as much as 80% happening within local communities [5] - Community providers play a crucial role in understanding the non-medical factors affecting health and wellness, such as transportation, diet, and employment [7][8] - A concerning trend of increasing cancer incidence in young adults is being observed in communities worldwide [9] The Role of Art & Science - The speaker draws a parallel between being an artist and a cancer researcher, highlighting the importance of inquisitiveness and questioning [1][2] - The speaker advocates for a more dynamic and inclusive view of human intellect and consciousness in cancer research, emphasizing the value of art and co-creative expression [13][14] Community & Helplessness - The speaker shares a personal experience of losing a friend to colon cancer, which led to the realization that helplessness is a choice [11][12] - Choosing community care is presented as the opposite of helplessness, emphasizing the power of collaboration and shared experience [16] - Community is defined as abundant action, pure service, and remembering and maintaining relationships with those who are missed [18][19][20]